MedTrace Logo

Study Evaluating the Pharmacokinetics of a Single Microdose of ACD856

NCT05783830 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-03-24

No results posted yet for this study

Summary

This is a Phase 0, open-label, non-controlled, single-centre study designed to evaluate the pharmacokinetics (PK) and safety and tolerability of a single, bolus intravenous (iv) injection of a microdose of ACD856 in healthy subjects.

Conditions

  • Cognition Disorder
  • Alzheimer Disease

Interventions

DRUG

ACD856

IV injection 100 mcg

Sponsors & Collaborators

  • AlzeCure Pharma

    lead INDUSTRY

Principal Investigators

  • Johan Sandin · AlzeCure Pharma

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-13
Primary Completion
2020-04-18
Completion
2020-04-18

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05783830 on ClinicalTrials.gov